30 patents
Utility
Pharmaceutical combination for the treatment of melanoma
12 Dec 23
The present invention relates to a pharmaceutical combination comprising a cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof; and at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor, for use in the treatment of melanoma.
Veena Agarwal, Giridharan Periyasamy, Maggie Rathos, Ankita Srivastava, Sreesha Srinivasa
Filed: 5 Feb 21
Utility
Compounds containing carbon-carbon linker as GPR120 agonists
3 Oct 23
Rajiv Sharma, Sanjay Kumar, Vishal Mahajan, Komal Bajaj, Pallavi Godse
Filed: 2 Nov 20
Utility
q1mopelfkr8j93ffjg6pauxp2youd62t9h0jl4mnebmqexhs
2 Jun 22
The present invention relates to a pharmaceutical combination comprising a CDK inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer.
Owe Orwar, Sreesha Srinivasa, Prabha Mishra
Filed: 13 Dec 21
Utility
gy0lvdlsw2i2z7rgzabfe30r5
1 Mar 22
The present invention relates to an oral pharmaceutical composition, particularly a tablet, comprising an active ingredient lurasidone or its pharmaceutically acceptable salt(s) or solvate(s) thereof and one or more pharmaceutical excipient(s); and a process for its preparation.
Tejas Shah, Milan B. Agrawal, Narendra Patel, Devesh Bhatt, Umesh Barabde, Vipan Dhall
Filed: 10 Jan 18
Utility
66l1nhw etn3t4ivsswj1tp2eeg6e
1 Feb 22
The present invention relates to a pharmaceutical combination comprising a CDK inhibitor and at least one antioxidant enzyme inhibitor for use in the treatment of cancer.
Owe Orwar, Sreesha Srinivasa, Prabha Mishra
Filed: 23 Dec 19
Utility
ghjjlxd1xbv6ukaajwdd3llozegiduri7a21vvlyaxs9fp3xinmx6jh w1ev
27 Jan 22
The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a diastereoisomer thereof for use in the treatment of cancers associated with human papillomavirus.
Swati Ajay PIRAMAL, Muralidhara Padigaru, Veena R. Agarwal, Gandhali Ashwin Deshpande
Filed: 29 Sep 21
Utility
koa0jhvlyhoawm654vbztw88z5iyxhgh282x2i246p3z30 8w1f3wk
23 Dec 21
The present invention relates to a pharmaceutical combination comprising a cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof; and at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor, for use in the treatment of melanoma.
Veena AGARWAL, Giridharan PERIYASAMY, Maggie RATHOS, Ankita SRIVASTAVA, Sreesha SRINIVASA
Filed: 5 Feb 21
Utility
ndbfakd6xef3lee5fx6eqhlzc6ltwykp
14 Dec 21
Milind Gharpure, Sanjay Kumar Sharma, Sandesh Vishwasrao, Prasad Vichare, Dipak Varal
Filed: 9 May 18
Utility
4l4a1gsb88kbhto2uuayyuixy2hid 19
2 Nov 21
The present invention relates to the pyrrolidine substituted with flavone derivatives, represented by the compounds of Formula (I) or a pharmaceutically acceptable salt, a solvate, a stereoisomer or a diastereoisomer thereof for use in the treatment of cancers associated with human papillomavirus.
Swati Ajay Piramal, Muralidhara Padigaru, Veena R. Agarwal, Gandhali Ashwin Deshpande
Filed: 9 Apr 20
Utility
6dbi9lqx0om9mol010q410wshn5t3
10 Aug 21
The present invention relates to a compound of formula I, or an isotopic form, stereoisomer, a tautomer, a pharmaceutically acceptable salt, a solvate, a polymorph, a prodrug, N-oxide or S-oxide thereof; and processes for their preparation.
Rajiv Sharma, Bichismita Sahu, Sunil Vasantrao Mali, Deepak Singh, Pramod Bhaskar Kumar, Mahesh Dawange, Hitesh Mistry
Filed: 25 Mar 15
Utility
9hrhyeo0q1z76jlljozf6y3m5g2z
1 Jul 21
Veena Agarwal, Arun Balakrishnan, Giridharan Periyasamy
Filed: 15 Mar 21
Utility
n4ovp60bxnuc7mmvlong0a4puqnk7i 2rqyercci8u6k2ndr3g2
20 May 21
Milind GHARPURE, Sanjay Kumar SHARMA, Sandesh VISHWASRAO, Prasad VICHARE, Dipak VARAL
Filed: 9 May 18
Utility
od10s870w8kqh7rmcda4ek6aomesdl4r5g3b1fkq2wzitb6ho0
18 May 21
The present invention relates to a pharmaceutical combination comprising a cyclin dependent kinase (CDK) inhibitor represented by a compound of formula I (as described herein) or a pharmaceutically acceptable salt thereof; and at least one anticancer agent selected from a BRAF inhibitor or a MEK inhibitor, for use in the treatment of melanoma.
Veena Agarwal, Giridharan Periyasamy, Maggie Rathos, Ankita Srivastava, Sreesha Srinivasa
Filed: 11 Jul 14
Utility
gwyhrm3o914jeh50zdovv
22 Apr 21
The present invention relates to an improved asymmetric synthesis of alpha-branched amines (hereafter referred to as the compound) and relative chiral amines (1″) or its pharmaceutically acceptable salt and derivatives.
Rajender Reddy LELETI, Sharadsrikar KOTTURI, Yogesh WAMAN, Chirag PATEL, Aditya PATWA, Rajesh SHENOY
Filed: 17 Apr 19
Utility
v6eu4js0ab7xme1fn hqlczoyn0sishl2igy34ktzkx6s5c4a7c4tr1cc229
25 Mar 21
The present invention relates to a novel crystalline polymorphic form of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]-piperazine hydrochloride; commonly known as vortioxetine hydrochloride (hereafter referred to as the compound (Ia) and process for its preparation comprising of treating the compound (Ia) (as described herein) with a ketone solvent or mixture of ketone solvent with other solvents.
Milind GHARPURE, Sanjay Kumar SHARMA, Nainesh KANSAGARA, Yogesh ZALTE, Pravin THOMBRE, Sudha MENON
Filed: 5 Feb 19
Utility
9l38nbgj71twpx1fdnezdhb2gczo18 ws8qsxlxb5uc6obgsevr9almy
9 Mar 21
Rajiv Sharma, Sanjay Kumar, Vishal Mahajan, Komal Bajaj, Pallavi Godse
Filed: 2 Feb 16
Utility
w32b946jyillp8c8ig o1yre7r
4 Mar 21
The present invention relates to an improved asymmetric synthesis of alpha-(diarylmethyl) alkyl amines (hereafter referred to as the compound (1)) or its pharmaceutically acceptable salt and derivatives.
Rajender Reddy LELETI, Sharadsrikar KOTTURI, Yogesh WAMAN, Chirag PATEL, Rajesh SHENOY
Filed: 20 Mar 19
Utility
1b0y2934dimitp3g1glavzuk4usdlocqo184m2pk4cr7d5oj
25 Feb 21
Rajiv SHARMA, Sanjay KUMAR, Vishal MAHAJAN, Komal BAJAJ, Pallavi GODSE
Filed: 2 Nov 20
Utility
y2f7liysmr60nqo 09ny2f0t1jfdiryuc4ii8wtxdwnijbiiqe2s60tes4d
11 Nov 20
The present invention provides an improved process for preparation of the L-threo-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) or a salt thereof, which is known as Droxidopa; comprising (a) recovery of the by-product compound (V) (as described herein) from the crude compound (I), and (b) recycling and re-use it for the preparation of droxidopa.
Milind GHARPURE, Ashutosh JAGTAP, Changdev RAUT, Navnath PATIL, Prashant LADKAT, Jaisankar KRISHNAPILLAI, Nirmal Kumar MANOHARAN, Kumaravel KANDASAMY
Filed: 2 Jan 19
Utility
pfxrz4nkec7zqpqjzfytgj0cgn28bfgw6vow5gemw7y6z3ye8q
23 Sep 20
The present invention provides an improved process for preparation of L-threo-(2S,3R)-3-(3,4-dihydroxyphenyl)serine (I) (Droxidopa) and its salts; comprising (a) reaction of the aldehyde compound (III) (as described herein) with Metal complex (II) (as described herein), and (h) hydrolysis of the compound (IV) obtained from step (a) in presence of acid.
Milind GHARPURE, Ashutosh JAGTAP, Changdev RAUT, Nainesh KANSAGARA, Jaisankar KRISHNAPILLAI, Nirmal Kumar MANOHARAN, Navnath PATIL
Filed: 27 Mar 17